Acrux Limited · ASX:ACR
Acrux — FY2015 Earnings Presentation
17 slides from Acrux's earnings presentation, Aug 20, 2015
Slide 1: Acrux
For personal use only Acrux Michael Kotsanis CEO and Managing Director Sharon Papworth CFO and Company Secretary Felicia Colagrande Product Development and Technical Affairs Director August 20, 2015 1
Slide 2: Forward-looking statements
Forward-looking statements For personal use only This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Acrux to be mate
Slide 3: Agenda
Agenda For personal use only FY 2015 P&L, cashflow and dividend Strategy fundamentals Pipeline overview Formulation permeation data 3
Slide 4: Financial Summary
Financial Summary For personal use only FY15 FY14 • Dividend declared on 13 August - 6 cents per share, fully franked and Cash 23.1 25.8 payable 3 September Revenue 25.4 53.9 Milestone - 28.7 • Strong balance sheet Royalty 24.6 24.7 • $23.1 million cash on hand Other 0.8 0.5 • Nil Debt Expenses (8.6
Slide 5: Financial Summary: year on year earnings
Financial Summary Comparison of year on year earnings For personal use only $M • FY14 Milestones received $28.7 million • $0.7M upon filing of Acrux’s estradiol spray in Europe; $28.0 million upon achieving Axiron net sales hurdle • Royalty payable to Monash Investment Trust declined, payable on Acr
Slide 6: Axiron quarterly sales
Axiron quarterly sales (US$ millions) For personal use only Q3 2013 Q4 2013 Q1 2014 Q2 2014 Total FY 2014 US$40.6m US$53.9m US$39.5m US$47.1m US$181.1m Q3 2014 Q4 2014 Q1 2015 Q2 2015 Total FY 2015 US$36.3m US$47.6m US$39.1m US$32.4m US$155.4m Source: https://investor.lilly.com/results.cfm 6
Slide 7: Agenda
Agenda For personal use only FY 2015 P&L, cashflow and dividend Strategy fundamentals Pipeline overview Formulation permeation data 7
Slide 8: Framework for continued growth
Framework for continued growth For personal use only Pipeline projects Improved chemical entity portfolio Pipeline projects Generic portfolio Existing portfolio 2011 Timing of development 2025 8
Slide 9: Acrux Fundamentals
Acrux Fundamentals For personal use only Right Right ideas and organisational projects structure Focussed development on attractive projects 9
Slide 10: Agenda
Agenda For personal use only FY 2015 P&L, cashflow and dividend Strategy fundamentals Pipeline overview Formulation permeation data 10
Slide 11: Product Pipeline
Product Pipeline For personal use only Indication Product Name Formulation Pre-clinical Phase 1 Phase 2 Phase 3 Registration Commercial Partner(s) design development Hypogonadism Axiron® Eli Lilly Menopausal Estradiol MDTS® Perrigo symptoms USA – Evamist® Post-operative pain Recuvyra® Elanco in dogs
Slide 12: Agenda
Agenda For personal use only FY 2015 P&L, cashflow and dividend Strategy fundamentals Pipeline overview Formulation permeation data 12
Slide 13: Acrux Antifungal Proposition
Acrux Antifungal Proposition For personal use only Antifungal Development Program Brief Project: Antifungal Topical Product Formulation: Solution for topical Indication: For treatment of administration onychomycosis in finger nails and toe nails Dosing: Once a day Target profile • Fast drying time w
Slide 14: Acrux Once-a-Day Diclofenac Formulations
Acrux Once-a-Day Diclofenac Formulations For personal use only Antifungal Development Program Project: Topical diclofenac with superior delivery profile Approved comparator spray 3 doses Acrux spray Approved comparator 1 dose gel 2 doses Daily dose of Acrux Diclofenac formulation is 34-fold lower th
Slide 15: Acrux Once-a-Day Ibuprofen Formulations
Acrux Once-a-Day Ibuprofen Formulations For personal use only Antifungal Development Program Project: Topical ibuprofen with superior delivery profile Acrux Ibuprofen product formulations demonstrate faster uptake through human skin over existing competitor 15
Slide 16: Acrux Generic Pipeline
Acrux Generic Pipeline For personal use only Topical or Transdermal generic pipeline Project: Multiple identified generic targets Indication: various based on existing Dosing: same as comparator approved and marketed drugs • Generic development opportunities identified through screen of universe of
Slide 17: For personal use only
For personal use only 17